131I and thyroid-associated ophthalmopathy

European Journal of Endocrinology

Volumn 143, Issue 2, 2000, Pages 155-160

  Rasmussen, A K ^a   Nygaard, B ^a   Feldt Rasmussen, U ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; GLUCOCORTICOID; RADIOACTIVE IODINE;

AUTOIMMUNE DISEASE; CIGARETTE SMOKING; EYE DISEASE; GRAVES DISEASE; HUMAN; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REVIEW; THYROIDECTOMY; PATHOPHYSIOLOGY; THYROID GLAND;

EYE DISEASES; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; THYROID GLAND;

EID: 0033623684     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1430155     Document Type: Review

References (55)

1. Mechanisms of disease: Pathogenesis of Graves' ophthalmopathy
2. Thyroid antibodies in endocrine ophthalmopathy
3. Eyeing up Graves' ophthalmopathy
4. Role of the eye muscles in thyroid eye disease: Identification of the principal autoantigens
5. Cytokines in the evolution of Graves' ophthalmopathy
6. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy
7. Interleukin-1 receptor antagonist and soluble interleukin-1 receptor inhibit interleukin-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy
8. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves' ophthalmopathy
9. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism
10. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy
11. Effect of abnormal thyroid function on the severity of Graves' opthalmopathy
12. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: Prognostic factors and the role of methimazole
13. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
14. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
15. Smoking and risk of Graves' disease
16. Graves' ophthalmopathy and tobacco smoking
17. Smoking and endocrine ophthalmopathy: Impact of smoking severity and current vs life-time cigarette consumption
18. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy
19. A prospective study of the differential changes in serum thyroglobulin and its autoantbodies during propylthioruacil or radioiodine therapy of patients with Graves' disease
20. Subtle changes in serum thyrotrophin (TSH) and sex-hormone-binding globulin (SHBG) levels during long-term follow-up after radioactive iodine in multinodular non-toxic goitre
21. 131I therapy of multinodular goitre
22. Influence of treatment with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins in Graves' disease
23. Outcome of thyroid function in Graves' patients treated with radioiodine: Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage
24. 131I treatment in patients with non-toxic goiter
25. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters
26. 131I therapy
27. The transition of subacute thyroiditis to Graves' disease as evidenced by diagnostic imaging
28. Graves' disease occurring after subacute thyroiditis: Report of a case and review of the literature
29. Appearance of Graves' disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma
30. Graves' disease after percutaneous ethanol injection for the treatment of autonomous thyroid adenoma
31. Humoral autoimmune manifestation in subacute thyroiditis
32. The acute changes in thyroid stimulating immunoglobulins, thyroglobulin and thyroglobulin antibodies following subtotal thyroidectomy
33. Serum thyroglobulin and thyroglobulin autoantibodies in thyroid diseases. Pathogenic and diagnostic aspects
34. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T-cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
35. Studies on the pathogenesis of the ophthalmopathy of Graves' disease
36. Ophthalmopathy of Graves' disease: Outcome after treatment with radioactive iodine, surgery or antithyroid drugs
37. Radioiodine and aggravation of Graves' ophthalmopathy
38. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine
39. Ophthalmopathy of Graves' disease: A comparison between patients treated surgically and patients treated with radioiodide
40. Ophthalmopathy and hyperthyroidism: A Comparison between patients receiving different antithyroid treatments
41. Treatment of Graves' disease and the course of ophthalmopathy
42. Management of thyrotoxicosis in patients with ophthalmopathy: Antithyroid regimen determined primarily by ocular manifestations
43. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism
44. 131I treatment protocols for Graves' disease
45. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre
46. 131I treatment of non-toxic goiter
47. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism
48. Graves' ophthalmopathy after subtotal thyroidectomi and radioiodine therapy
49. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: A case-control study
50. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease
51. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study
52. Reassessment of antithyroid drug therapy of Graves' disease
53. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey
54. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism
55. Effect of the treatment of hyperthyroidism on the course of exopthalmos